Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

New five-year data support superiority of Novartis AG's drug Tasigna over Glivec in newly diagnosed Ph+ CML patients


Sunday, 8 Dec 2013 06:00pm EST 

Novartis AG:Says new five-year data support superiority of Novartis drug Tasigna over Glivec in newly diagnosed Ph+ CML patients.Says ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec.Says data demonstrated higher rates of early and deeper molecular response in newly diagnosed patients, including MR4.5, and a reduced risk of progression.Says separate study, ENESTcmr, confirms treatment with Tasigna led to deeper molecular response in patients who switch after long-term treatment with Glivec.Says new data show patients who failed to respond to frontline Glivec achieved higher rates of molecular response with switch to Tasigna versus Glivec dose escalation. 

Company Quote

81.3
0.2 +0.25%
9:33am EDT